Follicular Lymphoma | Topics

John P. Leonard, MD, on the FDA Approval of Tazemetostat for Follicular Lymphoma
October 27, 2020

In June 2020, the FDA approved tazemetostat (Tazverik) for 2 distinct follicular lymphoma indications based on overall response rate and duration of response observed in phase 2 clinical trial cohorts of patients with follicular lymphoma with EZH2 mutations and wild-type EZH2.

Phase 2 ELARA Trial Meets Primary End Point in R/R Follicular Lymphoma
August 04, 2020

Novartis announced that the study met its primary end point of complete response rate in patients with relapsed or refractory follicular lymphoma.

FDA Approves Tazemetostat for 2 Follicular Lymphoma Indications
June 18, 2020

The FDA approved tazemetostat for adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, as well as for adult patients with relapsed or refractory FL who have no satisfactory alternative treatment options.